Hexokinase 2 and cancer therapy
Hexokinase 2 and cancer therapy
批准号:
10437024
负责人:
Nissim Hay
金额:
$56.25万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-07-01 至 2026-06-30
关键词:
A kinase anchoring proteinAblationAddressAdultAffectApplications GrantsBindingBreast cancer metastasisCell SurvivalCellsCyclic AMP-Dependent Protein KinasesCytotoxic T-LymphocytesGene ExpressionGeneticGlucoseGlucose-6-PhosphateGlycogen Synthase Kinase 3GlycolysisGoalsHexokinase 2HistonesHumanImmunotherapyMCL1 geneMaintenanceMalignant NeoplasmsMalignant neoplasm of liverMalignant neoplasm of lungMalignant neoplasm of prostateMammary NeoplasmsMediatingMetabolicMetabolismMusNeoplasm MetastasisNormal CellNormal tissue morphologyNutrientOxidation-ReductionPhosphorylationPhosphotransferasesPositron-Emission TomographyProtein SubunitsProteinsRegulationResistanceRoleScaffolding ProteinTissuesadverse outcomecancer cellcancer therapycheckpoint therapyfluorodeoxyglucose positron emission tomographyglucose metabolismglycosylationhexokinaseknock-downmalignant breast neoplasmmouse modelneoplasm immunotherapyneoplastic cellnovelprogrammed cell death ligand 1recruitresponsescaffoldsuccesstargeted cancer therapytumortumor growthtumor microenvironmenttumor progressiontumorigenesis
中文摘要
癌细胞在代谢上不同于正常的配对细胞,这体现在
癌细胞的葡萄糖代谢率很高。癌症中的高糖代谢率
细胞至少部分是由于己糖激酶(HK2)表达的显著诱导,这是
在大多数正常细胞中不表达。大多数正常成人组织和细胞都表达己糖激酶1
(HK1),但当它们转化为癌细胞时,它们开始表达高水平的HK2。因此,香港2
可能是癌细胞的标志,并可能成为癌症治疗的靶点。多年来,我们
提供了HK2可在小鼠体内系统缺失以抑制癌症的概念的遗传学证据
而不会有不良后果。我们发现,HK2的缺乏抑制了启动和
肺癌、乳腺癌、肝癌和前列腺癌小鼠模型中癌症的维持
癌症。同样,在人类癌细胞中可诱导的HK2基因敲除抑制了人癌细胞的生长
肿瘤形成后的肿瘤。在这项拨款申请中,我们会调查新的HK2活动,包括
以前都没有被勘探过。这些活动包括:(I)香港天文台一项新颖的月光功能,
与其葡萄糖激酶活性无关。这种活性可以决定某些物质的稳定性
MCL1、NRF2和Snail等与细胞存活、氧化还原调节、
EMT和转移分别为。(Ii)HK2在糖基化、肿瘤微环境中的作用
和免疫疗法。(Iii)HK2通过组蛋白乳糖化作用对基因表达的影响。
英文摘要
Cancer cells are metabolically different from normal matching cells, and this is manifested by the
high rate of glucose metabolism in cancer cells. The high rate of glucose metabolism in cancer
cells is, at least in part, due to the marked induction of hexokinase (HK2) expression, which is
not expressed in most normal cells. Most normal adult tissues and cells express hexokinase 1
(HK1), but when they convert into cancer cells, they start expressing high levels HK2. Thus, HK2
could be a hallmark of cancer cells and could be targeted for cancer therapy. Over the years we
provided genetic proofs of concept that HK2 can be systemically deleted in mice to inhibit cancer
without adverse consequences. We showed that HK2 deficiency inhibited both initiation and
maintenance of cancer in mouse models of lung cancer, breast cancer, liver cancer, and prostate
cancer. Likewise, inducible knockdown of HK2 in human cancer cells inhibited the growth of
tumors after tumor formation. In this grant application we will investigate novel HK2 activities that
were not previously explored. These activities include: (i) A novel moonlighting function of HK2,
independently of its glucose kinase activity. This activity could determine the stability of certain
proteins such as MCL1, NRF2, and SNAIL that are associated with cell survival, redox regulation,
and EMT and metastasis respectively. (ii) A role of HK2 in glycosylation, tumor microenvironment
and immunotherapy. (iii) The effect of HK2 on gene expression through histone lactylation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Hexokinase 2 and cancer therapy
-
批准号:10299101
-
项目类别:
-
资助金额:$49.05万
-
财政年份:2021
-
负责人:Nissim Hay
-
依托单位:
Hexokinase 2 and cancer therapy
-
批准号:10661677
-
项目类别:
-
资助金额:$56.25万
-
财政年份:2021
-
负责人:Nissim Hay
-
依托单位:
The role of AMPK and CD36 in breast cancer tumorigenesis and metastasis
-
批准号:10377328
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2021
-
负责人:Nissim Hay
-
依托单位:
The role of AMPK and CD36 in breast cancer tumorigenesis and metastasis
-
批准号:10618782
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2021
-
负责人:Nissim Hay
-
依托单位:
Research Career Scientist Award
-
批准号:9763758
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:Nissim Hay
-
依托单位:
Research Career Scientist Award
-
批准号:10454208
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:Nissim Hay
-
依托单位:
Research Career Scientist Award
-
批准号:10618282
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:Nissim Hay
-
依托单位:
Research Career Scientist Award
-
批准号:9911969
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:Nissim Hay
-
依托单位:
Research Career Scientist Award
-
批准号:10265395
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:Nissim Hay
-
依托单位:
Hexokinase 2 in liver cancer
-
批准号:9195585
-
项目类别:
-
资助金额:$39.82万
-
财政年份:2016
-
负责人:Nissim Hay
-
依托单位:
Hexokinase 2 and cancer therapy
-
批准号:8696773
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:Nissim Hay
-
依托单位:
Hexokinase 2 and cancer therapy
-
批准号:8512527
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:Nissim Hay
-
依托单位:
Hexokinase 2 and cancer therapy
-
批准号:8330561
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:Nissim Hay
-
依托单位:
Hexokinase 2 and cancer therapy
-
批准号:10171394
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:Nissim Hay
-
依托单位:
Akt, cellular senescence, and lifespan
-
批准号:7223511
-
项目类别:
-
资助金额:$30.32万
-
财政年份:2006
-
负责人:Nissim Hay
-
依托单位:
Akt, cellular senescence, and lifespan
-
批准号:7584082
-
项目类别:
-
资助金额:$29.71万
-
财政年份:2006
-
负责人:Nissim Hay
-
依托单位:
Akt, cellular senescence, and lifespan
-
批准号:7394933
-
项目类别:
-
资助金额:$29.71万
-
财政年份:2006
-
负责人:Nissim Hay
-
依托单位:
Akt, cellular senescence, and lifespan
-
批准号:7033151
-
项目类别:
-
资助金额:$31.23万
-
财政年份:2006
-
负责人:Nissim Hay
-
依托单位:
Akt, cellular senescence, and lifespan
-
批准号:7795180
-
项目类别:
-
资助金额:$29.42万
-
财政年份:2006
-
负责人:Nissim Hay
-
依托单位:
P13K/PTEN/Akt (PKB), Signaling and genesis of cancer
-
批准号:6866717
-
项目类别:
-
资助金额:$35.58万
-
财政年份:2001
-
负责人:Nissim Hay
-
依托单位:
海外基金